Accelerated iTBS for Post Partum Depression

Post Partum Depression Clinical Trial

Official title:

An Open Label Study to Assess the Feasibility and Tolerability of Accelerated Theta Burst Repetitive Transcranial Magnetic Stimulation (iTBS-rTMS) for the Treatment of Post-Partum Depression

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03417960
• Other study ID #: Pro00073886
• Status: Recruiting
• Phase: N/A
• Start date: January 24, 2018
• Est. completion date: July 31, 2024

Study information

• Verified date: April 2024
• Source: Medical University of South Carolina
• Contact: Lisa McTeague, PhD
• Phone: 843-792-8274
• Email: mcteague[@]musc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators are studying the feasibility and tolerability of 10x/day intermittent theta burst (excitatory) transcranial magnetic stimulation to the left dorsolateral prefrontal cortex over the course of 6 days for women with post-partum depression. The investigators further hope to characterize the anticipated anti-depressant effect of this treatment paradigm.

Description:

This is an open-label study designed to investigate the feasibility and tolerability of a novel TMS treatment protocol to treat depression in women with post-partum depression. It is known that TMS can effectively treat depression. The FDA approved protocol lasts 6 weeks and is not feasible for many women with post-partum depression. The investigators are investigating a 6 day treatment for depression which may be more acceptable for this population. The investigators further hope to characterize the ant-depressant effect of this protocol in order to design a larger trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: July 31, 2024
• Est. primary completion date: May 31, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Participants must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.

2. Participants must be over the age of 18.

3. Participants must meet criteria for post-partum depression: a) onset of symptoms in the first year postpartum

4. Participants must have a HRSD17 greater than or equal to 14 at baseline.

Exclusion Criteria:

1. Participants must not be pregnant.

2. Participants must not meet moderate or severe use disorder of any substance with the exception of Tobacco Use Disorder.

3. Participants must not have current psychotic symptoms.

4. Participants must not have a history of dementia or other cognitive impairment.

5. Participants must not have active suicidal ideation requiring hospitalization or a suicide attempt within the past 3 months.

6. Participants must not have any contraindications to receiving rTMS (e.g. metal implanted above the neck, history of seizure, any known brain lesion).

7. Participants must not have any unstable general medical conditions.

8. Participants must not have had eclampsia during pregnancy.

Related Conditions & MeSH terms

• Depression
• Depression, Postpartum
• Depressive Disorder
• Post Partum Depression

Intervention

Device:
• iTBS
The investigators will treat post-partum depressed subjects with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. The accelerated paradigm will consist of 10 such sessions separated by 15 minutes, for three treatment days per week. There will be 2 weeks of 10 sessions on each of three days for a total of six treatment days, divided by one treatment-free week between treatment weeks. Treatments will be delivered at the 10-20 EEG coordinate for F3 (approximating the left DLPFC), and will be found using the Beam-F3 method.

Locations

Country	Name	City	State
United States	Medical University of South Carolina	Charleston	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine feasibility and tolerability of accelerated iTBS for postpartum depression. The investigators hope to retain >80% of recruited patients (feasibility) and reach a full treatment dose of 120%rMT in >80% of enrolled women (tolerability).	Determine feasibility and tolerability of accelerated iTBS for postpartum depression. The investigators hope to retain >80% of recruited patients (feasibility) and reach a full treatment dose of 120%rMT in >80% of enrolled women (tolerability).	7 days
Secondary	Anti-depressant effect	Determine the preliminary anti-depressant effect size of a course of accelerated iTBS for women with postpartum depression. We hypothesize that at least 30% of post-partum depressed subjects receiving accelerated iTBS will achieve a response (50% reduction in symptoms as measured on Ham-D) at 4 weeks.	4 weeks